NO20011356D0 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrrolopyrimidines as protein kinase inhibitorsInfo
- Publication number
- NO20011356D0 NO20011356D0 NO20011356A NO20011356A NO20011356D0 NO 20011356 D0 NO20011356 D0 NO 20011356D0 NO 20011356 A NO20011356 A NO 20011356A NO 20011356 A NO20011356 A NO 20011356A NO 20011356 D0 NO20011356 D0 NO 20011356D0
- Authority
- NO
- Norway
- Prior art keywords
- pyrrolopyrimidines
- protein kinase
- kinase inhibitors
- inhibitors
- protein
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10083298P | 1998-09-18 | 1998-09-18 | |
| US10083398P | 1998-09-18 | 1998-09-18 | |
| US10083498P | 1998-09-18 | 1998-09-18 | |
| US10094698P | 1998-09-18 | 1998-09-18 | |
| PCT/US1999/021560 WO2000017203A1 (en) | 1998-09-18 | 1999-09-17 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20011356D0 true NO20011356D0 (en) | 2001-03-16 |
| NO20011356L NO20011356L (en) | 2001-05-16 |
Family
ID=27493158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011356A NO20011356L (en) | 1998-09-18 | 2001-03-16 | Pyrrolopyrimidines as protein kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1114053A1 (en) |
| JP (1) | JP2002526500A (en) |
| KR (1) | KR20010085824A (en) |
| CN (1) | CN1335849A (en) |
| AU (1) | AU753555C (en) |
| BG (1) | BG105346A (en) |
| BR (1) | BR9913887A (en) |
| CA (1) | CA2344249A1 (en) |
| CZ (1) | CZ2001960A3 (en) |
| HK (1) | HK1039326A1 (en) |
| HU (1) | HUP0200403A3 (en) |
| ID (1) | ID29028A (en) |
| IL (1) | IL141866A0 (en) |
| NO (1) | NO20011356L (en) |
| NZ (1) | NZ510588A (en) |
| PL (1) | PL346700A1 (en) |
| SK (1) | SK3842001A3 (en) |
| TR (1) | TR200101186T2 (en) |
| WO (1) | WO2000017203A1 (en) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
| EP1107957B1 (en) | 1998-08-29 | 2006-10-18 | AstraZeneca AB | Pyrimidine compounds |
| AU5438499A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| UA72290C2 (en) | 1999-12-10 | 2005-02-15 | Пфайзер Продактс Інк. | COMPOUNDS OF PYRROLO[2.3-d]PYRIMIDINE, A PHARMACEUTICAL COMPOSITION (VARIANTS), A METHOD FOR INHIBITION OF PROTEINKINASES OR JANUS KINASE 3 (VARIANTS) |
| US6780858B2 (en) * | 2000-01-13 | 2004-08-24 | Tularik Inc. | Antibacterial agents |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
| CN100351253C (en) * | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| AR035885A1 (en) | 2001-05-14 | 2004-07-21 | Novartis Ag | DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AU2003208479A1 (en) | 2002-03-09 | 2003-09-22 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| KR20050086784A (en) | 2002-11-26 | 2005-08-30 | 화이자 프로덕츠 인크. | Method of treatment of transplant rejection |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| GB0302748D0 (en) * | 2003-02-06 | 2003-03-12 | Novartis Ag | Organic compounds |
| AU2004220327B2 (en) | 2003-03-12 | 2010-06-24 | Pfizer Products Inc. | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| AR045037A1 (en) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE. |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MXPA06005578A (en) * | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Pyrrolopyrimidine compounds useful in treatment of cancer. |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| EP1730148A4 (en) * | 2004-02-03 | 2009-08-19 | Abbott Lab | Aminobenzoxazoles as therapeutic agents |
| AR048518A1 (en) | 2004-04-02 | 2006-05-03 | Osi Pharm Inc | PROTEIN KINASE HETEROBICICLIC INHIBITORS REPLACED WITH RINGS 6,6-BICYCLES |
| MXPA06013805A (en) | 2004-05-27 | 2007-02-02 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives useful in cancer treatment. |
| AR053090A1 (en) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | IMIDAZOTRIAZINS AS PROTEIN KINASE INHIBITORS AND THEIR USE FOR THE PREPARATION OF MEDICINES |
| TW200626142A (en) * | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| JP2008533172A (en) * | 2005-03-17 | 2008-08-21 | ノバルティス アクチエンゲゼルシャフト | N- [3- (1- (1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl) as a tyrosine / threonine kinase inhibitor, in particular a B-RAF kinase inhibitor ) -Phenyl] benzamide |
| EP1874769B1 (en) * | 2005-04-25 | 2011-09-14 | Merck Patent GmbH | Novel aza- heterocycles serving as kinase inhibitors |
| US8062838B2 (en) | 2005-09-20 | 2011-11-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
| CA2627839C (en) * | 2005-11-02 | 2014-08-19 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| AR057960A1 (en) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | BICYCLE PROTEIN QUINASE INHIBITORS |
| AU2007215161A1 (en) * | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-C) pyridines useful as inhibitors of protein kinases |
| BRPI0711358A2 (en) | 2006-05-09 | 2011-09-27 | Pfizer Prod Inc | cycloalkylamino acid derivatives and their pharmaceutical compositions |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| BRPI0917459B1 (en) | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-METHYL-1- [TRANS-4- [METHYL (7H-PYRROL [2,3-D] PYRIDOL [2,3-D] PYRIMIDINE COMPOUNDS, USE OF THESE IN THERAPY AND CRYSTALLINE AS N-METHYL-PYRIMIDIN -4-YL) AMINO] CYCLOHEXYL} METHANOSULPHONAMIDE |
| CA2740885C (en) * | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| MX2011004824A (en) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | USE OF CATHOLIC BUTANE DERIVATIVES IN THERAPY AGAINST CANCER. |
| WO2010084944A1 (en) * | 2009-01-22 | 2010-07-29 | 田辺三菱製薬株式会社 | NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND |
| JP2012518657A (en) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Combined anticancer treatment |
| WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2424368B1 (en) * | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| CN103492390A (en) * | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | Fluorophenyl bicyclic heteroaryl compounds |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| AU2012283775A1 (en) | 2011-07-13 | 2014-01-23 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| JP5826931B2 (en) | 2011-07-19 | 2015-12-02 | メルク・シャープ・エンド・ドーム・ベー・フェー | 4-Imidazopyridazin-1-yl-benzamide and 4-Imidazotriazin-1-yl-benzamide as BTK inhibitors |
| JP6342805B2 (en) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Substituted pyrazolo [3,4-D] pyrimidine and uses thereof |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| CA2863239C (en) | 2012-01-31 | 2016-09-13 | Beta Pharma Canada Inc. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2878601B1 (en) * | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
| KR20150061651A (en) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Modulation of ire1 |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
| US9624224B2 (en) | 2013-09-30 | 2017-04-18 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| ES2685661T3 (en) * | 2013-11-08 | 2018-10-10 | Ono Pharmaceutical Co., Ltd. | Pyrrolopyrimidine derivative |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| CA2834528A1 (en) * | 2013-11-26 | 2015-05-26 | Pharmascience Inc. | Protein kinase inhibitors |
| AU2015225745B2 (en) * | 2014-02-03 | 2017-04-20 | Cadila Healthcare Limited | Heterocyclic compounds |
| LT3179991T (en) | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | THERAPEUTIC COMBINATIONS OF BTK INHIBITOR AND BCL-2 INHIBITOR |
| WO2017096323A1 (en) * | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| MY207239A (en) * | 2018-09-13 | 2025-02-08 | Kissei Pharmaceutical | Imidazopyridinone compound |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| BR112022002698A2 (en) | 2019-08-14 | 2022-07-19 | Incyte Corp | IMIDAZOLYL PYRIMIDYNYLAMINE COMPOUNDS AS CDK2 INHIBITORS |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| MX2022004390A (en) * | 2019-10-11 | 2022-08-08 | Incyte Corp | Bicyclic amines as cdk2 inhibitors. |
| CN112961159B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidopyrazole/pyrrole derivatives and preparation method and use thereof |
| CN112961158B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidopyrazole/pyrrole derivatives and preparation method and use thereof |
| JP7504822B2 (en) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | Pharmaceutical Compositions Containing Imidazopyridinone Compounds |
| AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CA3247064A1 (en) * | 2022-03-31 | 2023-10-05 | Acerand Therapeutics (Hong Kong) Limited | Spirobicyclic compounds |
| CN117402161A (en) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | Sulfoxide imine compound with FGFR inhibition effect, pharmaceutical composition containing sulfoxide imine compound and application of sulfoxide imine compound |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3036390A1 (en) * | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
| FI933303L (en) * | 1991-01-23 | 1993-08-31 | Gensia Inc | ADENOSINCINE INHIBITORS |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| EP0783505B1 (en) * | 1994-09-29 | 2001-03-07 | Novartis AG | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| CH690773A5 (en) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo (2,3-d) pyrimides and their use. |
| WO1997032879A1 (en) * | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES |
| CA2249739A1 (en) * | 1996-03-15 | 1997-09-25 | Novartis Ag | Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use |
| JP2001516353A (en) * | 1997-03-19 | 2001-09-25 | ビーエーエスエフ アクチェンゲゼルシャフト | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors |
-
1999
- 1999-09-17 PL PL99346700A patent/PL346700A1/en unknown
- 1999-09-17 NZ NZ510588A patent/NZ510588A/en unknown
- 1999-09-17 HU HU0200403A patent/HUP0200403A3/en unknown
- 1999-09-17 BR BR9913887-5A patent/BR9913887A/en not_active IP Right Cessation
- 1999-09-17 TR TR2001/01186T patent/TR200101186T2/en unknown
- 1999-09-17 JP JP2000574112A patent/JP2002526500A/en active Pending
- 1999-09-17 SK SK384-2001A patent/SK3842001A3/en unknown
- 1999-09-17 CA CA002344249A patent/CA2344249A1/en not_active Abandoned
- 1999-09-17 CN CN99813217A patent/CN1335849A/en active Pending
- 1999-09-17 HK HK02100227.3A patent/HK1039326A1/en unknown
- 1999-09-17 AU AU60484/99A patent/AU753555C/en not_active Ceased
- 1999-09-17 WO PCT/US1999/021560 patent/WO2000017203A1/en not_active Ceased
- 1999-09-17 KR KR1020017003532A patent/KR20010085824A/en not_active Ceased
- 1999-09-17 IL IL14186699A patent/IL141866A0/en unknown
- 1999-09-17 CZ CZ2001960A patent/CZ2001960A3/en unknown
- 1999-09-17 EP EP99969415A patent/EP1114053A1/en not_active Withdrawn
- 1999-09-17 ID IDW20010652A patent/ID29028A/en unknown
-
2001
- 2001-03-15 BG BG105346A patent/BG105346A/en unknown
- 2001-03-16 NO NO20011356A patent/NO20011356L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20011356L (en) | 2001-05-16 |
| AU753555B2 (en) | 2002-10-24 |
| HUP0200403A3 (en) | 2004-07-28 |
| BR9913887A (en) | 2001-10-23 |
| AU753555C (en) | 2003-07-03 |
| KR20010085824A (en) | 2001-09-07 |
| CN1335849A (en) | 2002-02-13 |
| AU6048499A (en) | 2000-04-10 |
| ID29028A (en) | 2001-07-26 |
| HK1039326A1 (en) | 2002-04-19 |
| JP2002526500A (en) | 2002-08-20 |
| SK3842001A3 (en) | 2002-04-04 |
| EP1114053A1 (en) | 2001-07-11 |
| CZ2001960A3 (en) | 2001-10-17 |
| HUP0200403A2 (en) | 2002-06-29 |
| CA2344249A1 (en) | 2000-03-30 |
| BG105346A (en) | 2001-12-29 |
| PL346700A1 (en) | 2002-02-25 |
| WO2000017203A1 (en) | 2000-03-30 |
| TR200101186T2 (en) | 2001-10-22 |
| IL141866A0 (en) | 2002-03-10 |
| NZ510588A (en) | 2003-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20011356L (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| NO20011575D0 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors | |
| NO20011574D0 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors | |
| DK1460072T3 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| ID30460A (en) | INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN | |
| NO20021239D0 (en) | Pteridinones as kinase inhibitors | |
| ATE318603T1 (en) | PYRROLOTRIAZINE KINASE INHIBITORS | |
| NO20002121D0 (en) | Benzothiazol-protein-tyrosine kinase inhibitors | |
| NO20023713D0 (en) | 2-benzothiazolyl-urea derivatives and their use as protein kinase inhibitors | |
| NO20035728L (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| NO20041887L (en) | Benzomidazoles useful as protein kinase inhibitors | |
| DK1337527T3 (en) | Indolylmaleinimide derivatives as protein kinase C inhibitors | |
| HUP0400300A3 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| NO990123D0 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| NO990124D0 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| DK2020408T3 (en) | Pyrrole-substituted 2-indolinone as protein kinase inhibitor | |
| DK1140840T3 (en) | omega-carboxyaryl-substituted diphenylureas as raf kinase inhibitors | |
| NO20015065D0 (en) | Pyrazolobenzodiazepines as CDK2 inhibitors | |
| DK0858452T3 (en) | Thiazole derivatives as protein kinase C inhibitors | |
| DE60101323D1 (en) | TRICYCLIC PROTEIN KINASE INHIBITORS | |
| ATE387448T1 (en) | 4,5-PYRAZINOXINDOLES AS PROTEIN KINASE INHIBITORS | |
| NO20016201D0 (en) | Tienopyrimidines as phosphodiesterase inhibitors | |
| EP1158982A4 (en) | PRENYLE PROTEIN TRANSFERASE INHIBITORS | |
| ATE252547T1 (en) | MATRIXMETALLOPROTEINASE INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |